Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Lung Cancer, Lung Adenocarcinoma, Lung Squamous Cell Carcinoma, Non Small Cell Lung Cancer. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
This study is a multi-center, observational, real-world study for patients with resected lung cancers in China. With the help of a properly designed data processing algorithm and extensively performed data quality assurance, this study aims to harness the potential of real-world big data to (1) describe characteristics and treatment patterns and their evolving trends; (2) discover features associated with overall survival; and (3) address recently-emerging clinical questions.
Detailed description
Lung cancer is the leading cause of cancer-related deaths in China. The recent decade witnessed rapid evolving of demographics, pathological features and prognoses of patients with surgically resected lung cancers. The introduction of minimally invasive surgery (MIS) concept and techniques, targeted therapy and immunotherapy changed treatment landscape for patients with surgically resected lung cancers. With more early-stage lung cancers discovered due to the application of CT screening, questions focusing on extent of lung resection, lymph node dissection, application of targeted or immune-therapy to early-stage lung cancers are emerging. This study aims to create a cohort of patients with surgically resected lung cancers and an analytic framework to address the aforementioned clinical questions.
Primary outcome measures
- Overall survival [Time frame: January 2014 to December 2031]
Secondary outcome measures (4)
- Baseline characteristics of included participants [Time frame: January 2014 to December 2028]
- Treatment patterns of included participants [Time frame: January 2014 to December 2028]
- Pathological characteristics of included participants [Time frame: January 2014 to December 2028]
- Features associated with overall survival [Time frame: First analysis is anticipated to be performed from April to August 2024; the final analysis is anticipated in 2032.]
Eligibility criteria
Inclusion criteria
- Age above 18.
- Have received surgical resection for lung malignancies.
Exclusion criteria
- Participants whose data are of low quality, poor completeness or poor internal linkage.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chine — Beijing
Identifiers
NCT: NCT06255197 · LungReal_01